DOCSLIB.ORG

Manufacturers with Signed Rebate Agreements February 2 , 2010

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Wisconsin Medicaid Pharmacy Data Table Manufacturers with Signed Rebate Agreements February 2 , 2010 NEW LABELER NAME START END SC NEW LABELER NAME START END SC 00002 ELI LILLY AND COMPANY 1/1/1991 Y 00126 COLGATE ORAL PHARMACEUTICAL 1/1/1991 Y 00003 E R SQUIBB AND SONS INC. 1/1/1991 Y 00131 SCHWARZ PHARMA, INC. 1/1/1991 Y 00004 HOFFMANN LAROCHE INC 1/1/1991 Y 00132 C B FLEET COMPANY INC. 1/1/1991 00005 LEDERLE LABORATORIES 1/1/1991 Y 00135 SMITHKLINE BEECHAM 1/1/1995 Y 00006 MERCK SHARP & DOHME 1/1/1991 Y 00143 WEST-WARD PHARMACEUTICAL C 1/1/1991 Y 00007 SMITHKLINE BEECHAM CORPORATI 1/1/1991 Y 00145 STIEFEL LABORATORIES INC. 1/1/1991 Y 00008 WYETH AYERST LABORATORIES 1/1/1991 Y 00149 PROCTER & GAMBLE PHARMACEU 1/1/1991 Y 00009 PHARMACIA AND UPJOHN 1/1/1991 Y 00165 BLAINE COMPANY, INC. 1/1/1992 00013 PHARMACIA AND UPJOHN 1/1/1991 Y 00168 E FOUGERA AND CO, DIV OF ALTAN 1/1/1991 Y 00015 INVAMED, INC 1/1/1991 Y 00169 NOVO NORDISK PHARMACEUTICAL 1/1/1991 Y 00023 ALLERGAN INC. 1/1/1991 Y 00172 ZENITH LABORATORIES, INC 1/1/1991 Y 00024 SANOFI SYNTHELABO 1/1/1991 00173 GLAXOSMITHKLINE 1/1/1991 Y 00025 PHARMACIA CORPORATION 1/1/1991 Y 00178 MISSION PHARMACAL COMPANY 1/1/1991 Y 00026 BAYER CORP PHARMACEUTICAL DI 1/1/1991 Y 00182 GOLDLINE LABORATORIES INC 1/1/1991 Y 00028 NOVARTIS PHARMACEUTICALS 1/1/1991 Y 00185 EON LABS MANUFACTURING, INC. 1/1/1991 Y 00029 SMITHKLINE BEECHAM CORPORATI 1/1/1991 Y 00186 ASTRAZENECA LP 1/1/1991 Y 00031 LEDERLE PIPERACILLIN 1/1/1991 Y 00187 ICN PHARMACEUTICALS INC. 1/1/1991 Y 00032 INTERNATIONAL LABORATORIES 1/1/1991 Y 00206 ELKINS-SINN 1/1/1991 Y 00037 CARTER- WALLACE, INC. 1/1/1991 Y 00212 SANDOZ NUTRITION 1/1/1991 00039 HOECHST MARION ROUSSEL INC. 1/1/1991 00224 KONSYL PHARMACEUTICALS, INC. 1/1/1992 00045 MCNEIL PHARMACEUTICAL 1/1/1991 Y 00225 B F ASHER COMPANY INC., 1/1/1991 00046 LEDERLE PARENTERALS 1/1/1991 Y 00228 PUREPAC PHARM. CO, DIV KALIPH 1/1/1991 Y 00049 PFIZER-ROERIG 1/1/1991 Y 00245 UPSHER-SMITH LABORATORIES IN 1/1/1991 Y 00051 UNIMED PHARMACEUTICALS, INC 10/1/1997 Y 00256 FLEMING AND COMPANY 10/1/1991 Y 00052 ORGANON INC. 1/1/1991 00258 INWOOD LABORATORIES INC 1/1/1991 Y 00053 AVENTIS BEHRING 1/1/1991 00259 MERZ PHARMACEUTICALS 1/1/1991 00054 ROXANE LABORATORIES, INC. 1/1/1991 Y 00264 B BRAUN MEDICAL, INC. 1/1/1991 00056 DU PONT PHARMACEUTICALS 1/1/1991 Y 00276 MISEMER PHARMACEUTICAL, INC. 10/1/2006 00062 ORTHO MCNEIL PHARMACEUTICAL 1/1/1991 Y 00277 LASER INC 1/1/1991 Y 00064 HEALTHPOINT LTD 7/1/1995 Y 00281 SAVAGE LABS, DIV OF ALTANA INC 1/1/1991 Y 00065 ALCON LABORATORIES, INC. 1/1/1991 Y 00288 FLUORITAB CORPORATION 10/1/1991 00066 DERMIK LABORATORIES 1/1/1991 00299 GALDERMA, L.T. 1/1/1991 00067 NOVARTIS CONSUMER HEALTH INC 1/1/1991 00300 TAP PHARMACEUTICALS INC 1/1/1991 Y 00068 HOECHST MARION ROUSSEL INC. 1/1/1991 00310 ASTRAZENECA LP 1/1/1991 Y 00069 PFIZER INC 1/1/1991 Y 00327 UNITED GUARDIAN, INC. 1/1/1991 Y 00071 WARNER-LAMBERT 1/1/1991 Y 00338 BAXTER HEALTHCARE CORPORATI 1/1/1991 Y 00072 APOTHECON INC 1/1/1991 00378 MYLAN PHARMACEUTICALS, INC. 1/1/1991 Y 00074 ABBOTT LABORATORIES 1/1/1991 Y 00406 MALLINCKRODT SPECIALTY CHEMI 7/1/1993 Y 00075 RHONE-POULENC RORER PHARMA 1/1/1991 00409 HOSPIRA, INC 1/1/2005 00078 NOVARTIS PHARMACEUTICALS 1/1/1991 Y 00414 SUPPOSITORIA LABORATORIES 4/1/1994 Y 00083 NOVARTIS PHARMACEUTICALS 1/1/1991 Y 00421 THE FIELDING PHARMACEUTICAL C 1/1/1991 Y 00085 SCHERING PLOUGH PHARMACEUTI 1/1/1991 00430 WARNER CHILCOTT LABORATORIE 1/1/1998 00087 BRISTOL-MYERS SQUIBB COMPAN 1/1/1991 Y 00456 FOREST PHARMACEUTICALS INC 1/1/1991 Y 00088 HOECHST MARION ROUSSEL, INC. 1/1/1991 00462 PHARMADERM 7/1/2003 00089 3M PHARMACEUTICALS 1/1/1991 Y 00469 LYPHOMED DIVISION FUJISAWA US 1/1/1991 Y 00091 KREMERS URBAN CO. 1/1/1991 Y 00472 ALPHARMA, USPD 1/1/1991 Y 00093 TEVA PHARMACEUTICALS 1/1/1991 Y 00482 BRADLEY PHARMACEUTICALS, INC. 1/1/1991 Y 00095 ECR PHARMACEUTICALS 7/1/1993 Y 00485 EDWARDS PHARMACEUTICALS, IN 1/1/1991 Y 00096 PERSON & COVEY INC. 4/1/1999 00486 BEACH PRODUCTS INC 1/1/1991 Y 00113 L. PERRIGO COMPANY 7/1/2003 00487 NEPHRON PHARMACEUTICALS CO 4/1/1992 Y 00115 GLOBAL PHARMACEUTICAL COMPA 1/1/1991 Y 00496 FERNDALE LABORATORIES INC. 1/1/1991 Y 00116 XTTRIUM LABORATORIES, INC 1/1/2002 Y 00517 AMERICAN REGENT LABS, INC. 7/1/1993 00121 PHARMACEUTICAL ASSOCIATES, IN 1/1/1991 Y 00525 PAN AMERICAN LABORATORIES IN 1/1/1991 Y Page 1 of 6 N = NEW; D = DELETED; X = COVERED (NO REBATE AGREEMENT); Y=SENIORCARE REBATE AGREEMENT ON FILE Wisconsin Medicaid Pharmacy Data Table Manufacturers with Signed Rebate Agreements February 2 , 2010 NEW LABELER NAME START END SC NEW LABELER NAME START END SC 00527 LANNETT COMPANY INC. 7/1/1994 Y 11098 AKORN MANUFACTURING 1/1/1996 Y 00535 GILBERT LABORATORIES 7/1/2002 Y 11383 WEEKS & LEO CO., INC. 2/23/2009 00536 WATSON PHARMA, INC 1/1/1991 Y 11399 GTX, INC 7/1/2005 Y 00548 INTERNATIONAL MEDICATION SYS 1/1/1991 Y 11523 SCHERING PLOUGH HEALTHCARE 4/1/2003 00555 BARR LABORATORIES INC 1/1/1991 Y 11528 CENTRIX PHARMACEUTICAL, INC 7/1/2006 Y 00573 WYETH AYERST LABORATORIES 1/1/1991 11530 GLAXOSMITHKLINE 4/1/2002 Y 00574 PADDOCK LABORATORIES, INC. 1/1/1991 Y 11701 COLOPLAST CORPORATION 10/1/1991 Y 00575 BAKER NORTON PHARMACEUTICA 1/1/1991 Y 11980 ALLERGAN INC 1/1/1991 Y 00590 DU PONT PHARMACEUTICALS 1/1/1991 Y 12496 RECKITT & COLMAN PHARMACEUTI 1/1/1994 00591 WATSON PHARMA, INC 7/1/2001 Y 12593 RED RIIVER PHARMA MANUFACTU 4/1/2006 00597 BOEHRINGER INGELHEIM PHARMA 1/1/1991 Y 12830 R.A. MCNEIL 1/1/1991 Y 00603 QUALITEST PRODUCTS, INC. 1/1/1991 Y 12939 MARLOP PHARMACEUTICALS, INC. 1/1/1991 00615 VANGUARD LABS, INC 1/1/1991 Y 12948 NITROMED INC 10/1/2005 00641 ESI LEDERLE, INC 1/1/1991 Y 13107 AUROBINDO PHARMA USA, INC 7/1/2005 Y 00642 EVERETT LABORATORIES 1/1/1991 Y 13279 ALLAN PHARMACEUTICALS, LLC 10/1/2005 00677 UNITED RESEARCH LABORATORIE 1/1/1991 Y 13310 A R SCIENTIFIC, INC 1/1/2006 Y 00682 MARNEL PHARMACEUTICALS INC 1/1/1991 13436 VENUS 1/1/2009 00703 GENSIA SICOR PHARMACEUTICALS 7/1/1992 Y 13453 GRACEWAY PHARMACEUTICALS, L 4/1/2007 Y 00713 G AND W LABORATORIES INC 1/1/1991 Y 13478 BARRIER THERAPEUTICS 1/1/2006 00777 DISTA PRODS CO DIV OF ELI LILLY 1/1/1991 Y 13533 TALECRIS BIOTHERAPEUTICS, INC 10/1/2005 00781 GENEVA PHARMACEUTICALS, INC., 1/1/1991 Y 13548 CORIA LABORATORIES, LTD 4/1/2006 00785 UAD LABORATORIES INC 1/1/1991 Y 13551 FSC LABORATORIES, INC 1/1/2006 00813 PHARMICS INC. 1/1/1991 13632 ROSEMONT PHARMACEUTICALS LT 7/1/2007 00832 USL PHARMA, INC 1/1/1991 Y 13668 TORRENT PHARM, INC. 10/1/2007 Y 00884 PEDINOL PHARMACAL INC 1/1/1991 Y 13811 TRIGEN LABORATORIES, INC. 4/1/2006 00904 MAJOR PHARMACEUTICALS 1/1/1991 Y 13845 DBA THE CHAO CENTER 4/30/2009 X 00941 BAXTER 12/1/1992 13913 DEPOMED, INC 10/1/2005 00944 BAXTER BIOTECH 1/1/1991 13925 SETON PHARMACEUTICALS, LLC 11/18/2008 00955 SANOFI SYNTHELABO 1/1/1996 14168 STONEBRIDGE PHARMA , LLC 1/1/2007 Y 00998 ALCON -PUERTO RICO- INC. 1/1/1991 Y 14508 SUN PHARMACEUTICAL INDUSTRIE 7/1/2006 Y 08880 KENDALL HEALTHCARE PRODUCT 1/1/1991 15054 TERCICA, INC 4/1/2006 08884 SHERWOOD MEDICAL 1/1/1991 15127 SELECT BRAND DISTRIBUTORS 10/1/2006 10019 BAXTER HEALTHCARE CORPORATI 10/1/2001 Y 15210 OTN GENERICS, INC. 10/1/2006 10122 CORNERSTONE BIOPHARM, INC 7/1/2005 15330 GENPHARM, L.P. 4/1/2006 Y 10139 GENERALMEDIX, INC. 12/9/2008 15338 APACE KY, LLC 1/1/2009 Y 10144 ACORDA THERAPEUTICS, INC 10/1/2005 15370 CARWIN ASSOCIATES, INC. 10/1/2006 Y 10147 PATRIOT PHARMACEUTICALS, LLC 4/1/2005 Y 15456 ESPRIT PHARMA, INC. 4/1/2006 Y 10148 COTHERIX, INC 7/1/2005 15584 BRISTOL-MYERS SQUIBB & GILEAD 7/1/2006 Y 10158 GLAXOSMITHKLINE 4/1/2002 Y 15686 MIDLAND HEALTHCARE, LLC 4/1/2006 10267 CONTRACT PHARMACAL CORP 1/1/1991 Y 15821 FOCUS LABORATORIES, INC. 10/1/2006 10337 DOAK DERMATOLOGICS DIV 7/1/2002 Y 16103 PHARBEST PHARMACEUTICALS, IN 10/1/2006 10370 ANCHEN PHARMACEUTICALSINC 7/1/2007 16252 COBALT LABORATORIES, INC 10/1/2006 Y 10454 SOLSTICE NEUROSCIENCES, INC 1/1/2006 16477 LASER PHARMACEUTICALS, LLC 7/1/2006 Y 10518 DABUR ONCOLOGY, PLC. 10/1/2007 16571 PACK PHARMACEUTICALS, L.L.C. 4/1/2006 Y 10542 HILLESTAD INTERNATIONAL, INC. 4/1/1994 Y 16714 NORTHSTAR RX, LLC 4/1/2008 Y 10572 AFFORDABLE PHARMACEUTICALS, 1/1/2005 Y 16729 ACCORD HEALTHCARE INC. 7/1/2008 Y 10631 RANBAXY LABORATORIES INCORP 10/1/2005 16781 ONSET THERAPEUTICS 7/1/2006 10702 KVK TECH INC 1/1/2007 Y 16887 VERNALIS PHARMACEUTICALS INC 10/1/2006 10768 PERRIGO PHARMACEUTICALS CO 4/1/2005 17205 LAYTON BIOSCIENCE, INC 1/1/2001 10892 LUNSCO INC 1/1/1991 Y 17314 ALZA CORPORATION 1/1/1991 Y 10914 BRIGHTON PHARMACEUTICALS, IN 1/1/2006 17433 ENEMEEZ INC 4/1/2007 Y 10922 INTENDIS, INC 10/1/2005 17478 AKORN INC 1/1/1991 Y 11042 ADVANCIS PHARMACEUTICAL 1/1/2006 Y 18011 ZERIS PHARMA, LLC.
Recommended publications
  • 2009: Turning the Corner

    2009: Turning the Corner

    data page 2009: Turning the corner Walter Yang Despite the shaky start to 2009, the biotech sector regained its financial Although initial public offerings showed signs of resuscitation (at least footing. Biotech indices were up, as were offerings and partnership mon- 13 more companies are now in the queue), follow-on financings came in ies. Excluding collaborations, the sector raised a total of $24.3 billion. above $6 billion—the second-best year over the past decade. Stock market performance Global biotech industry financing Although biotech indices were up ~16% last year, they underperformed The boost in partnership promises to US biotechs and follow-on financings other major indices. pushed industry funding to $61.3 billion, up 82% from 2008. 1,500 Swiss Market S&P 500 2009 36.9 10.0 5.1 2.2 6.0 0.9 1,400 NASDAQ Biotech Dow Jones 2008 20.0 3.2 5.3 3.1 1.9 0.1 1,300 NASDAQ BioCentury 100 2007 22.4 11.7 6.8 4.7 4.4 3.0 1,200 Partnering 2006 19.8 11.9 5.6 4.7 5.6 2.0 1,100 Year Debt and other Index 17.3 6.1 5.4 2.7 4.8 1.9 1,000 2005 Venture capital PIPEs 900 2004 10.9 8.8 5.3 2.9 3.3 2.6 Follow-ons 800 2003 8.9 9.1 4.0 2.2 3.9 0.5 IPOs 700 010203040506070 Amount raised ($ billions) 1/09 2/09 3/09 4/09 5/09 6/09 7/09 8/09 9/09 12/08 Month ending 10/09 11/09 12/09 Partnership figures are for deals involving a US company.
  • Essex Hangar Aircrafi: Challenger (Schering Plough) Tail Number: N34CD Flight Time: 50 Minutes

    Essex Hangar Aircrafi: Challenger (Schering Plough) Tail Number: N34CD Flight Time: 50 Minutes

    This document is from the collections at the Dole Archives, University of Kansas http://dolearchives.ku.edu ... DRAFT# 1- 8/26/94 ·- Contact: Mo Taggart 703/684-7848 Jo-Anne Coe 703/845-1714 SENATOR DOLE SCHEDULE ~ AUGUST 30, 1994 -NEW YORK TUESDAY. AUGUST 30 .. 1".4 10:35 am DEPART Capitol for National Airport Ori ver: Wilbert 10:50 am ARRIVE National Airport and proceed to departing aircraft PBO: Signature 703/419·8440 10:55 am DEPART Wushington for Morristown, NJ FBO: Essex Hangar Aircrafi: Challenger (Schering Plough) Tail number: N34CD Flight time: 50 minutes Pilots: Curt Barsi John Santucci Seats: 6 Meal: None Manifest: Senator Dole Rob Lively, Schcring Plough Mike Glassner • Mark Miller Contact: Rob Lively 202/463-8809 11:45 am ARRIVE Morristown, NJ FBO: Essex Hangar 201/539-6554 11 :50 am DEPART airport for Shering Plough Headquarters Driver: Mr. Luciano's driver Drive time: 5 minutes J,ocation: l Giralda Fanns Madison, NJ 11 :55 am ARRIVE Schering Plough Headquarters 20 I /822-7440 Page 1 of 48 This document is from the collections at the Dole Archives, University of Kansas http://dolearchives.ku.edu TUESDAY, AUGUSI-.3D .1994 PAGE TWO 12:00 N- ATTEND Lunch with Bob Luciano, Chairman of Schering Plough 1:30 pm 1:30 pm DEPART Schering Plough Headquarters for airport Driver: Mr. Luciano's driver Drive time: 5 minutes 1:35 pm ARRIVE airport and proceed to departing heliocopter FBO: Essex Hangar 201/539-6554 1:40 pm DEPART Morristown, NJ for New York Helo pad: 34th Strecf Helo pad Aircraft: S-76 .
  • Transcept Pharmaceuticals, Inc

    Transcept Pharmaceuticals, Inc

    Table of Contents SCHEDULE 14A (RULE 14A 101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by x Definitive Proxy Statement Rule 14a-6(e)(2)) ¨ Definitive Additional Materials ¨ Soliciting Material Pursuant to §240.14a-12 Transcept Pharmaceuticals, Inc. (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): x No fee required. ¨ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: ¨ Fee paid previously with preliminary materials. ¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: Table of Contents NOTICE OF ANNUAL MEETING OF STOCKHOLDERS JUNE 23, 2011 To Our Stockholders: NOTICE IS HEREBY GIVEN that the Annual Meeting of Stockholders of Transcept Pharmaceuticals, Inc., a Delaware corporation, will be held on Thursday, June 23, 2011, at 8:30 a.m., local time, at our office located at 1003 West Cutting Blvd., Suite 110, Point Richmond, California 94804, for the following purposes: 1.
  • Manufacturers and Wholesalers Street

    Manufacturers and Wholesalers Street

    Nevada AB128 Code of Conduct Compliant Companies Manufacturers and Wholesalers Street City ST Zip 10 Edison Street LLC 13 Edison Street LLC Abbott Diabetes Care Division Abbott Diagnostic Division Abbott Electrophysiology (including Kalila Medical 2- 2016)) Abbott Laboratories 100 Abbott Park Road, Dept. EC10, Bldg. APGA-2 Abbott Park IL 60064 Abbott Medical Optics Abbott Molecular Division Abbott Nutrition Products Division Abbott Vascular Division (includes Tendyne 9-2015) AbbVie, Inc. 1 N. Waukegan Road North Chicago IL 60064 Acadia Phamaceuticals 3611 Valley Centre Drive, Suite 300 San Diego CA 92130 Accelero Health Partners, LLC Acclarent, Inc. 1525-B O'Brien Dr. Menlo Park CA 94025 Accuri Cyometers, Inc. Ace Surgical Supply, Inc. 1034 Pearl St. Brockton MA 02301 Acorda Therapeutics, Inc. 420 Sawmill River Road Ardsley NY 10532 AcriVet, Inc. Actavis W.C. Holding, Inc. Morris Corporate Center III, 400 Interpace Parkway Parsippany NJ 07054 Actavis , Inc. Actelion Pharmaceuticals US, Inc. 5000 Shoreline Court, Suite 200 S. San Francisco CA 94080 Activis 400 Interpace parkway Parsippany NJ 07054 A-Dec, Inc. 2601 Crestview Dr. Newberg OR 97132 Advanced Respiratory, Inc. Advanced Sterilization Products 33 Technology Drive Irvine CA 92618 Advanced Vision Research, Inc., dba Akorn Consumer Health Aegerion Pharmaceuticals, Inc. 101 Main Street, Suite 1850 Cambridge MA 02142 Aesculap Implant Systems, Inc. Aesculap, Inc. 3773 Corporate Parkway Center Valley PA 18034 Aesthera Corporation Afaxys, Inc. PO Box 20158 Charleston SC 29413 AGMS, Inc. Akorn (New Jersey) Inc. Page 1 of 23 Pages 2/15/2017 Nevada AB128 Code of Conduct Compliant Companies Akorn AG (formerly Excelvision AG) Akorn Animal Health, Inc.
  • 05/01/02 Louisiana Medicaid Management

    05/01/02 Louisiana Medicaid Management

    APPENDIX C 05/01/02 LOUISIANA MEDICAID MANAGEMENT INFORMATION SYSTEM PAGE 1 DEPT OF HEALTH AND HOSPITALS - BUREAU OF HEALTH SERVICES FINANCING LOUISIANA MEDICAID PHARMACY BENEFITS MANAGEMENT UNIT ONLY THESE COMPANIES PRODUCTS ARE COVERED AND ONLY THOSE DOSAGE FORMS LISTED IN APPENDIX A. MEDICAID DRUG FEDERAL REBATE PARTICIPATING PHARMACEUTICAL COMPANIES LABELER PHARMACEUTICAL COMPANY EFFECTIVE END DATE CODE DATE 00002 ELI LILLY & CO 04/01/91 00003 E.R.SQUIBB & SONS,INC 04/01/91 00004 HOFFMAN-LA ROCHE,INC 04/01/91 00005 LEDERLE LABORATORIES AMERICAN CYANAMID 04/01/91 00006 MERCK SHARP & DOHME 04/01/91 00007 SMITHKLINE BEECHAM CORPORATION 04/01/91 00008 WYETH LABORATORIES 04/01/91 00009 THE UPJOHN COMPANY 04/01/91 00011 BECTON DICKINSON MICROBIOLOGY SYSTEMS 10/01/91 07/01/98 00013 ADRIA LABORATORIES DIV.OF ERBAMONT,INC 04/01/91 00014 G.D.SEARLE & CO 04/01/91 01/01/01 00015 MEAD JOHNSON & COMPANY 04/01/91 00016 KABI PHARMACIA 04/01/91 00021 REED & CARNRICK 10/01/96 01/01/97 00023 ALLERGAN,INC 04/01/91 00024 WINTHROP PHARMACEUTICALS 04/01/91 00025 G.D.SEARLE & CO 04/01/91 00026 MILES INC.,PHARMACEUTICAL DIVISION 04/01/91 00028 GEIGY PHARMACEUTICALS 04/01/91 00029 SMITHKLINE BEECHAM CORPORATION 04/01/91 00031 ROBINS,A.H. 04/01/91 00032 SOLVAY PHARMACEUTICALS 04/01/91 00033 SYNTEX 04/01/91 00034 THE PURDUE FREDERICK COMPANY 04/01/91 00037 CARTER-WALLACE,INC 04/01/91 00038 STUART PHARMACEUTICALS,ICI AMERICAS INC 04/01/91 07/01/01 00039 HOECHST-ROUSSEL PHARMACEUTICALS INC 04/01/91 00043 SANDOZ CONSUMER CORPORATION 04/01/91 00044 KNOLL PHARMACEUTICALS
  • Pfizer's Bourla

    Pfizer's Bourla

    No. 3985 December 13, 2019 line success and business development. “In the next two years, we need to see how the pipeline is delivering,” he said. Bourla has been outspoken that when it comes to business development, he doesn’t see a mega-merger on the hori- zon. Instead, he said he is looking to bring in mid-stage clinical development assets to complement the internal pipeline. It sounds like investors can expect the company to be active on the business development front within those guard- rails. “I want to double it,” he said of the pipeline, which includes 92 projects right now. “And, we are going to double it by bringing in a lot of innovation to comple- ment what we distribute.” The company is focusing business de- velopment on six core therapeutic areas Pfizer’s Bourla: “I Think We Forgot as well, but Bourla indicated the company will be actively building out those areas both through internal investment and What It Looks Like To Grow” external collaboration. “We’re going to be JESSICA MERRILL [email protected] active because Pfizer is a very big plane and it cannot fly with one engine,” he said. fizer Inc. CEO Albert Bourla took in July it will merge the Upjohn business Bourla highlighted Pfizer’s recent acqui- over the top leadership spot from with Mylan NV to form a new generic drug sition of the cancer specialist Array Bio- PIan Read a year ago, but has quickly company to be called Viatris GMBH. Pharma for $11.4bn as an example of the executed on big changes poised to make The resulting Pfizer will be significantly kinds of deals the company will be pursu- Pfizer significantly smaller and faster smaller, with a 2020 annual revenue base ing.
  • Health Industry Business Communications Council

    Health Industry Business Communications Council

    Health Industry Business Communications Council Registered Labelers: Accredited Auto-ID Labeling Standards Argentina New MedTek Devices Pty Ltd Oxavita SRL Norseld Pty Ltd. Novadien Healthcare Pty Ltd The following companies Odontit S.A. (and/or their subsidiaries/ PAMPAMED S.R.L. Numedico Technologies Pty Ltd divisions) have applied PATEJIM SRL Opto Global Pty. Ltd. for a Labeler Identification Orthocell Limited Code (LIC) assignment with Austria Prolotus Technologies Pty Ltd HIBCC*. By doing so, they afreeze GmbH Red Milawa Pty Ltd dba Magic Mobility have demonstrated their AMI GmbH SDI Limited commitment to patient safety Bender Medsystems GmbH Signostics Ltd. and logistical efficiency for BHS Technologies GmbH Sirtex Medical Pty Ltd their customers, the industry Metasys Medizintechnik GmbH Smith & Nephew Surgical Pty. Ltd. and the public at large. PAA Laboratories GmbH Staminalift International Limited Safersonic Medizinprodukte Handels The Pipette Company Pty. Ltd. Any organization that is GmbH Thermo Electron Corporation interested in using the HIBC W & H Dentalwerk Burmoos GmbH Vush Pty Ltd uniform labeling system may apply for the assignment of VUSH STIMULATION Australia one or more LICs. William A Cook Australia Pty. Ltd. Adv. Surgical Design & Manufacture, Ltd. Last updated 9-21-2021 AirPhysio Pty Ltd Belgium Annalise-AI Pty Ltd 3M Europe Apollo Medical Imaging Technology Pty Advanced Medical Diagnostics SA/NV Ltd Analis SA/NV Benra Pty Ltd dba Gelflex Laboratories Baxter World Trade Bioclone Australia Pty. Ltd. Bio-Rad RSL Candelis, Inc. Bio-Rad Lab Inc Clinical Diag. Group DePuy Australia Pty. Ltd. Biosource Europe SA For more information, please dorsaVi Ltd Cilag NV contact the HIBCC office at: EC Certification Service GmbH Coris Bioconcept Fink Engineering Pty Ltd Fuji Hunt Photographic Chemicals NV 2525 E.
  • Overview of Ftc Antitrust Actions in Pharmaceutical Services and Products

    Overview of Ftc Antitrust Actions in Pharmaceutical Services and Products

    OVERVIEW OF FTC ANTITRUST ACTIONS IN PHARMACEUTICAL SERVICES AND PRODUCTS Health Care Division Bureau of Competition Federal Trade Commission Washington D.C. 20580 Markus H. Meier Assistant Director Bradley S. Albert Deputy Assistant Director Saralisa C. Brau Deputy Assistant Director September 2009 TABLE OF CONTENTS Page I. INTRODUCTION. ........................................................... 1 II. CONDUCT INVOLVING PHARMACEUTICAL SERVICES AND PRODUCTS. 3 A. Monopolization. ...................................................... 3 B. Agreements Not to Compete. ............................................ 8 C. Agreements on Price or Price-Related Terms. 14 D. Agreements to Obstruct Innovative Forms of Health Care Delivery or Financing. 20 E. Illegal Tying and Other Arrangements. .................................... 20 III. PHARMACEUTICAL MERGERS. ........................................... 20 A. Horizontal Mergers Between Direct Competitors. 20 B. Potential Competition Mergers. ......................................... 44 C. Innovation Market Mergers. ............................................ 47 D. Vertical Mergers...................................................... 49 IV. INDUSTRY GUIDANCE STATEMENTS...................................... 50 A. Advisory Opinions. ................................................... 50 B. Citizen Petition to the Food and Drug Administration. 51 V. AMICUS BRIEFS. ......................................................... 51 VI. INDICES. ............................................................
  • Chrysler Affiliate Rewards Program

    Chrysler Affiliate Rewards Program

    Chrysler Affiliate Rewards Program If you or your spouse work, or have retired from, one of the companies listed below, you may qualify for pricing as low as 1% Below Factory Invoice on a New FIAT! Check the list of companies below to see if your company qualifies.* A F O AAA-- State of Ohio Members Freightliner Of Tampa, Llc Ocala Freightliner ABB, Inc. Freightliner Of Toledo OCE'- North America Abbott Labs Freightliner Of Utah, Llc Ocean Freightliner, Ltd. Abbott, Nicholson, Quilter, Freightliner Trucks So. Florida Inc. O'connor Gmc, Inc. Esshaki & Youngblood PC Freightliner Twin Ports O'connor Truck Sales, Inc. Abercrombie & Fitch Freightmasters Ohio Machinery Company AboveNet Fresenius Medical dba Ohio CAT Abraxis Bioscience Inc. Fresno Truck Center Oklahoma City Freightliner Accor North America FRIENDLY MOTORCARS Oklahoma Farm Bureau Ace Hardware Corporation Fru-Con Construction Corporation Oklahoma Publishing Company, Action Western Star Fujisawa Healthcare Inc. The (OPUBCO) Actelion Pharmaceuticals US, Inc. Ftl And Ws Of Maine Old Dominion Freight Lines Action Couriers Ftl And Wst Of Tifton Oldcastle Inc. ADVANTAGE Health Solutions, Inc. Ftl Stl Wst Of Odessa Omaha Truck Center Inc Advance Publications Ftl Trucks Of South Florida Omni Care Health Plan Aearo Company Ftl, Stl And Wst Of Montgomery One Call Locators Aetna Ftl,Stl, and Western Star Of Dothan One Source Management Inc Affinia Group Fyda Freightliner Cincinnati Oracle Corporation Agar Truck Sales, Inc. Fyda Freightliner Columbus,Inc Organon Pharmaceuticals USA, Inc. AGCO Corporation Fyda Freightliner Pittsburgh Orlando Freightliner AGFA Corporation Fyda Freightliner Youngstown Orlando Freightliner South Aggreko, LLC ORRIN B HAYES, INC. Agricredit Acceptance LLC G Oscient Pharmaceuticals Agrilink Foods OSI Pharmaceuticals Gabrielli Ford Truck Sales AGSTAR Financial Services Otjen, Van Ert, Stangle, Lieb & Weir, S.C.
  • Manufacturers with Signed Rebate Agreements February 1 , 2011

    Manufacturers with Signed Rebate Agreements February 1 , 2011

    Wisconsin Medicaid Pharmacy Data Table Manufacturers with Signed Rebate Agreements February 1 , 2011 NEWLABELER NAME START END SC NEW LABELER NAME START END SC 00002 ELI LILLY AND COMPANY 1/1/1991 Y 00126 COLGATE ORAL PHARMACEUTICAL 1/1/1991 Y 00003 E R SQUIBB AND SONS INC. 1/1/1991 Y 00131 SCHWARZ PHARMA, INC. 1/1/1991 Y 00004 HOFFMANN LAROCHE INC 1/1/1991 00132 C B FLEET COMPANY INC. 1/1/1991 00005 LEDERLE LABORATORIES 1/1/1991 Y 00135 SMITHKLINE BEECHAM 1/1/1995 Y 00006 MERCK SHARP & DOHME 1/1/1991 Y 00143 WEST-WARD PHARMACEUTICAL C 1/1/1991 Y 00007 SMITHKLINE BEECHAM CORPORATI 1/1/1991 Y 00145 STIEFEL LABORATORIES INC. 1/1/1991 Y 00008 WYETH AYERST LABORATORIES 1/1/1991 Y 00149 PROCTER & GAMBLE PHARMACEU 1/1/1991 Y 00009 PHARMACIA AND UPJOHN 1/1/1991 Y 00168 E FOUGERA AND CO, DIV OF ALTAN 1/1/1991 Y 00013 PHARMACIA AND UPJOHN 1/1/1991 Y 00169 NOVO NORDISK PHARMACEUTICAL 1/1/1991 Y 00015 INVAMED, INC 1/1/1991 Y 00172 ZENITH LABORATORIES, INC 1/1/1991 Y 00023 ALLERGAN INC. 1/1/1991 Y 00173 GLAXOSMITHKLINE 1/1/1991 Y 00024 SANOFI SYNTHELABO 1/1/1991 Y 00178 MISSION PHARMACAL COMPANY 1/1/1991 Y 00025 PHARMACIA CORPORATION 1/1/1991 Y 00182 GOLDLINE LABORATORIES INC 1/1/1991 Y 00026 BAYER CORP PHARMACEUTICAL DI 1/1/1991 Y 00185 EON LABS MANUFACTURING, INC. 1/1/1991 Y 00028 NOVARTIS PHARMACEUTICALS 1/1/1991 Y 00186 ASTRAZENECA LP 1/1/1991 Y 00029 SMITHKLINE BEECHAM CORPORATI 1/1/1991 Y 00187 ICN PHARMACEUTICALS INC.
  • CONCERT PHARMACEUTICALS, INC. (Exact Name of Registrant As Specified in Its Charter)

    CONCERT PHARMACEUTICALS, INC. (Exact Name of Registrant As Specified in Its Charter)

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material under §240.14a-12 CONCERT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): x No fee required. ¨ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: ¨ Fee paid previously with preliminary materials. ¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: 1 Concert Pharmaceuticals, Inc.
  • 28 May 2009 Thomas E. Costa

    28 May 2009 Thomas E. Costa

    The Third International Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum Thomas E. Costa 2828 MayMay 20092009 This presentation represents my own personal opinion and is not the official position of Bristol-Myers Squibb PhRMA Code 2009 • Updated in response to concerns of healthcare stakeholders • Reaffirms that interactions between pharmaceutical company representatives and healthcare professionals (HCPs) should: ¾ Inform HCPs about the benefits and risks of our products ¾ Provide scientific and educational information ¾ Obtain feedback and advice about our products through consultation with medical experts • The PhRMA Code is the new industry standard PhRMA Code Signatory Companies • Abbott • Eli Lilly and Company • Amgen, Inc. • Merck & Company, Inc. • Amylin Pharmaceuticals, Inc. • Millennium Pharmaceuticals, Inc. • Astellas US LLC • Novartis Pharmaceuticals • AstraZeneca LP Corporation • Bayer HealthCare • Novo Nordisk Inc. Pharmaceuticals • Otsuka America, Inc. • Boehringer Ingleheim • Ovation Pharmaceuticals, Inc. Pharmaceuticals, Inc. • Pfizer, Inc. • Bristol-Myers Squibb Company • Purdue Pharma LP • Cephalon, Inc. • sanofi-aventis US • Covidien Ltd. • Schering-Plough Corporation • Daiichi Sankyo, Inc. • Sepracor, Inc. • Eisai, Inc. • Signa-Tau Pharmaceuticals, Inc. • EMD Serono • Solstice Neurosciences, Inc. • Endo Pharmaceuticals, Inc. • Solvay Pharmaceuticals, Inc. • Genzyme Corporation • Takeda Pharmaceuticals North • GlaxoSmithKline America, Inc. • Hoffmann-La Roche, Inc. • Wyeth • Johnson and Johnson